2019
Breast Cancer Treatment
Waks AG, Winer EP. Breast Cancer Treatment. JAMA 2019, 321: 288-300. PMID: 30667505, DOI: 10.1001/jama.2018.19323.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerNonmetastatic breast cancerTriple-negative tumorsBreast cancerSystemic therapyTumor subtypesMetastatic triple-negative breast cancerHormone receptor-positive tumorsBreast cancer-specific survivalHuman epidermal growth factor 2Epidermal growth factor 2Small-molecule inhibitor therapyMajor tumor subtypesCancer-specific survivalMedian overall survivalProgesterone receptor expressionMetastatic breast cancerTime of diagnosisReceptor-positive tumorsBreast cancer treatmentErbB2-positive tumorsPreoperative treatment responseERBB2 gene amplificationDistinct risk profilesPalliating symptoms
2018
Variation in guideline-concordant care for elderly patients with metastatic breast cancer in the United States
Poorvu PD, Vaz-Luis I, Freedman RA, Lin NU, Barry WT, Winer EP, Hassett MJ. Variation in guideline-concordant care for elderly patients with metastatic breast cancer in the United States. Breast Cancer Research And Treatment 2018, 168: 727-737. PMID: 29332137, DOI: 10.1007/s10549-018-4659-4.Peer-Reviewed Original ResearchConceptsInitial systemic therapyMetastatic breast cancerSystemic therapyBreast cancerDe novo metastatic breast cancerNovo metastatic breast cancerEarly-stage breast cancerHuman epidermal receptor 2HR-positive patientsInitial systemic treatmentGuideline-concordant careHER2-positive patientsFirst-line therapyTriple-negative tumorsPatterns of careQuality of careGuideline concordanceInitial therapyMBC cohortUntreated patientsElderly patientsMost patientsSystemic treatmentInitial treatmentHospice utilization
2016
Subtype-Dependent Relationship Between Young Age at Diagnosis and Breast Cancer Survival
Partridge AH, Hughes ME, Warner ET, Ottesen RA, Wong YN, Edge SB, Theriault RL, Blayney DW, Niland JC, Winer EP, Weeks JC, Tamimi RM. Subtype-Dependent Relationship Between Young Age at Diagnosis and Breast Cancer Survival. Journal Of Clinical Oncology 2016, 34: 3308-3314. PMID: 27480155, DOI: 10.1200/jco.2015.65.8013.Peer-Reviewed Original ResearchConceptsMultivariable Cox proportional hazards modelsCox proportional hazards modelBreast cancer deathsProportional hazards modelBreast cancerYears of ageYounger ageCancer deathHazards modelHuman epidermal growth factor receptor 2 subtypeStage INational Comprehensive Cancer Network centersBreast cancer-specific survivalEarly-stage breast cancerYoung womenCancer-specific survivalSurvival of womenEarly breast cancerLuminal B tumorsBreast cancer mortalityTriple-negative tumorsBreast cancer survivalLuminal breast cancerBreast cancer recurrenceBreast cancer subtypes
2012
Clinicopathologic features, patterns of recurrence, and survival among women with triple‐negative breast cancer in the National Comprehensive Cancer Network
Lin NU, Vanderplas A, Hughes ME, Theriault RL, Edge SB, Wong Y, Blayney DW, Niland JC, Winer EP, Weeks JC. Clinicopathologic features, patterns of recurrence, and survival among women with triple‐negative breast cancer in the National Comprehensive Cancer Network. Cancer 2012, 118: 5463-5472. PMID: 22544643, PMCID: PMC3611659, DOI: 10.1002/cncr.27581.Peer-Reviewed Original ResearchConceptsHuman epidermal growth factor receptor 2Triple-negative tumorsHR-positive/HER2-negative tumorsHER2-negative tumorsTriple-negative subtypePatterns of recurrenceEstrogen receptorProgesterone receptorClinicopathologic featuresBreast cancerNational Comprehensive Cancer Network centersNational Comprehensive Cancer NetworkHigher body mass indexEpidermal growth factor receptor 2Triple-negative breast cancerLymph node involvementComprehensive Cancer NetworkGrowth factor receptor 2Triple-negative cancersRisk of deathBody mass indexAbnormal screening mammogramBreast cancer subtypesHigher tumor classificationFactor receptor 2
2007
Heterogeneity of breast cancer and implications of adjuvant chemotherapy
Razzak AR, Lin NU, Winer EP. Heterogeneity of breast cancer and implications of adjuvant chemotherapy. Breast Cancer 2007, 15: 31-34. PMID: 18224391, DOI: 10.1007/s12282-007-0007-y.Peer-Reviewed Original ResearchConceptsEstrogen receptor-positive tumorsReceptor-positive tumorsBreast cancerPositive diseasePositive tumorsAdjuvant chemotherapyDisease recurrenceClinical dataEstrogen receptor-positive cancersEstrogen receptor-negative cancersEstrogen-positive tumorsRole of chemotherapyUse of trastuzumabReceptor-positive cancersTriple-negative tumorsReceptor-negative cancersHigh nuclear gradeBreast cancer treatmentFamily of diseasesEndocrine therapyNodal statusNegative tumorsPositive cancersTumor sizeNegative cancers
2006
Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342
Harris LN, Broadwater G, Lin NU, Miron A, Schnitt SJ, Cowan D, Lara J, Bleiweiss I, Berry D, Ellis M, Hayes DF, Winer EP, Dressler L. Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Research 2006, 8: r66. PMID: 17129383, PMCID: PMC1797029, DOI: 10.1186/bcr1622.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerTriple-negative tumorsOverall survivalBreast cancerP53 statusNegative tumorsHER2 statusHormone receptorsHormone receptor statusShorter median timeDoses of paclitaxelLonger overall survivalHER2-positive tumorsAfrican American patientsHormone receptor expressionPrimary tumor tissuesAdvanced diseaseMetastatic diseaseShorter OSReceptor statusMedian timeTreatment failureShorter survivalCaucasian patientsPathology reports